GATA3 and asthma: Recently, effective targeting of the transcriptional regulator GATA3, which is being widely accepted to promote type 2 tissue immune responses by regulating gene expression on a transcriptional level in multiple immune cell subsets implied in the pathogenesis of allergic airway diseases, was reported to be achievable by local application of GATA-3-specific DNAzymes, thereby showing clinical efficacy in asthma patients (60, 61).